ESO Lymphoma Course
Should We Add Other Agents Like Obinutuzumab, Lenalidomide, Bortezomib or Ibrutinib to R-CHOP? How to Decide Which DLBCL Patients Should Receive CNS Prophylaxis?
By
ESO Lymphoma Course
FEATURING
Andrew Davies
By
ESO Lymphoma Course
FEATURING
Andrew Davies
Login to view comments.
Click here to Login